Johnson & Johnson reported sales of blood thinner Xarelto fell 19% to $549 million in the second quarter of 2019 compared with the same period in 2018 as increased discounts to Medicare patients took effect.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,